Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Calliditas Therapeutics Ab ADR (CALT)
Calliditas Therapeutics Ab ADR (CALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 679,121
  • Shares Outstanding, K 29,786
  • Annual Sales, $ 79,570 K
  • Annual Income, $ -40,860 K
  • 60-Month Beta 1.48
  • Price/Sales 8.53
  • Price/Cash Flow N/A
  • Price/Book 8.94
Trade CALT with:

Options Overview Details

View History
  • Implied Volatility 97.84% ( +97.84%)
  • Historical Volatility 106.34%
  • IV Percentile 31%
  • IV Rank 40.79%
  • IV High 173.46% on 10/21/22
  • IV Low 45.74% on 06/08/22
  • Put/Call Vol Ratio 0.25
  • Today's Volume 10
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 512
  • Open Int (30-Day) 401

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.51
  • Low Estimate -0.62
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +34.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.30 +39.88%
on 03/10/23
25.49 -10.55%
on 03/15/23
+4.14 (+22.19%)
since 02/24/23
3-Month
15.56 +46.57%
on 12/28/22
25.49 -10.55%
on 03/15/23
+5.50 (+31.79%)
since 12/23/22
52-Week
10.82 +110.72%
on 10/20/22
25.49 -10.55%
on 03/15/23
+3.53 (+18.32%)
since 03/24/22

Most Recent Stories

More News
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing

The high-flyers have soared to new heights and further gains could be up ahead.

TVTX : 20.88 (+2.45%)
RETA : 85.69 (-2.57%)
CALT : 22.80 (unch)
NEO : 16.87 (-7.10%)
Everest Medicines Announces Partner Calliditas Therapeutics Reports Positive Topline Results from Phase 3 NefIgArd Trial Evaluating Nefecon in IgA Nephropathy

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq...

CALT : 22.80 (unch)
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global,...

CALT : 22.80 (unch)
New Strong Sell Stocks for February 27th

ATUS, CALT and CRC have been added to the Zacks Rank #5 (Strong Sell) List on February 27, 2023.

CRC : 37.04 (+2.69%)
ATUS : 3.09 (unch)
CALT : 22.80 (unch)
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Medicines and Healthcare products...

CALT : 22.80 (unch)
New Strong Sell Stocks for January 6th

CALT, CVGW and DFH have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2023.

CVGW : 26.73 (+7.52%)
CALT : 22.80 (unch)
DFH : 12.69 (+1.93%)
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022

/PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net...

CALT : 22.80 (unch)
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") announced today that they have entered into an exclusive...

CALT : 22.80 (unch)
VTRS : 9.33 (+1.41%)
Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority...

CALT : 22.80 (unch)
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...

AUPH : 10.31 (+10.98%)
CALT : 22.80 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

See More

Key Turning Points

3rd Resistance Point 24.50
2nd Resistance Point 23.97
1st Resistance Point 23.39
Last Price 22.80
1st Support Level 22.28
2nd Support Level 21.75
3rd Support Level 21.17

See More

52-Week High 25.49
Last Price 22.80
Fibonacci 61.8% 19.89
Fibonacci 50% 18.15
Fibonacci 38.2% 16.42
52-Week Low 10.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar